FDA approves first generic Atacand
Sandoz has become the first company to gain the FDA approval to produce a generic version of Atacand (candesartan cilexetil), the popular heart drug that generated an estimated 120 million in domestic sales last year.
Sandoz has become the first company to gain FDA approval to produce a generic version of Atacand (candesartan cilexetil), the popular heart drug that generated an estimated $120 million in domestic sales last year.
“Sandoz is proud to be the first generic company to market this important generic treatment option to patients in the US,” said Don DeGolyer, president of Sandoz US. “The launch of candesartan further expands our offering of high-quality, affordable cardiology medicines.”
Candesartan cilexetil tablets are used to treat heart failure in some adults and hypertension in adults and children aged 1 to 17 years.
Sandoz’s generic candesartan cilexetil tablets will be available in 4-mg, 8-mg, 16-mg, and 32-mg strength tablets.
FDA and EMA Accepts Applications for New Nusinersen Regimen
January 23rd 2025An investigational higher dose of spinal muscular atrophy drug nusinersen gains attention as the FDA and European Medicines Agency (EMA) considerate it as an alternative than the current lower FDA-approved dosage.
Read More
